UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000010602
Receipt number R000012389
Scientific Title Randomized phase IIb/III trial of autologous tumor vaccine with temozolomide for newly diagnosed glioblastoma.
Date of disclosure of the study information 2013/04/26
Last modified on 2021/09/15 18:08:53

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Randomized phase IIb/III trial of autologous tumor vaccine with temozolomide for newly diagnosed glioblastoma.

Acronym

AFTV-GBM-PIIb/III

Scientific Title

Randomized phase IIb/III trial of autologous tumor vaccine with temozolomide for newly diagnosed glioblastoma.

Scientific Title:Acronym

AFTV-GBM-PIIb/III

Region

Japan


Condition

Condition

newly diagnosed glioblastoma

Classification by specialty

Neurosurgery

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To evaluate the efficacy of autologous tumor vaccine to prevent recurrence and/or cure residual tumor for patients with newly diagnosed glioblastoma.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2


Developmental phase

Phase II,III


Assessment

Primary outcomes

overall survival

Key secondary outcomes

1) Cause-specific survival
2) Progression-free survival
3) Tumor-regression rate, disease-control rate
4) QOL
5) Neurological improvement


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit


Blinding

Double blind -all involved are blinded

Control

Placebo

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Vaccine

Interventions/Control_1

vaccine

Interventions/Control_2

non vaccine

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

16 years-old <=

Age-upper limit

75 years-old >=

Gender

Male and Female

Key inclusion criteria

1) 16 to 75 years of age.
2) Newly diagnosed and histologically confirmed glioblastoma (WHO grade IV) in supratentrial brain without dissemination.
3) Maximum surgical resection was performed.
4) Enough mass of tumor reserved as fixed specimen.
5) Karnofsky performance scale is equal to or more than 60 %, and life expectancy expected at least 3months.
6) Standard radiotherapy in 60 Gy will be performed.
7) Patient informed his/her diagnosis, and has enough ability to comprehend and consent to the study.
8) Vaccination and follow-up will perform under the institutions.

Key exclusion criteria

1) Patients who have been administered or are taking corticosteroid.
2) Patients who implantated of carmustine wafers in the surgical cavity.
3) Patients with high intracranical pressure.
4) Patients with severe myelosupression.
5) Patients with severe complication including hematopathy
6) Patients with malignant tumor or cancer except malignant glioma.
7) Pregnant or nursing woman, or woman willing to be pregnant.
8) Patients participate in other study during or within 6 months before temozolomide administration in this study.
9) Patients who has HBV or HCV.
10) Other reasons for exclusion

Target sample size

60


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Yoshihiro Muragakli

Organization

Tokyo Women's Medical University, Graduate School of Medicine

Division name

Faculty of Advanced Techno-Surgery, Institute of Advanced Biomedical Engineering & Science, Dep. of Neurosurgery, Neurological Institute

Zip code


Address

8-1 Kawada-cho Shinjuku-ku Tokyo 162-8666 Japan

TEL

03-5367-9945

Email

ymuragaki@twmu.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Takashi Maruyama

Organization

Tokyo Women's Medical University

Division name

Dep. of Neurosurgery, Neurological Institute

Zip code


Address

8-1 Kawada-cho Shinjuku-ku Tokyo 162-8666 Japan

TEL

03-3353-8111

Homepage URL


Email

tmaruyama@nij.twmu.ac.jp


Sponsor or person

Institute

Tokyo Women's Medical University

Institute

Department

Personal name



Funding Source

Organization

Cell Medicine Cooperation

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

東京女子医科大学附属病院(東京都)、筑波大学附属病院(茨城県)、大分大学附属病院(大分県)、日赤医療センター(東京都)、熊本大学(熊本県)、東北大学(宮城県)、京都大学(京都府)


Other administrative information

Date of disclosure of the study information

2013 Year 04 Month 26 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled

63

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2012 Year 12 Month 27 Day

Date of IRB

2013 Year 01 Month 31 Day

Anticipated trial start date

2013 Year 03 Month 01 Day

Last follow-up date

2017 Year 07 Month 04 Day

Date of closure to data entry

2017 Year 08 Month 31 Day

Date trial data considered complete


Date analysis concluded

2017 Year 10 Month 16 Day


Other

Other related information



Management information

Registered date

2013 Year 04 Month 26 Day

Last modified on

2021 Year 09 Month 15 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000012389


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name